A generic version of Cabergoline 0.5 mg, a medication used to treat hyperprolactinemia and Parkinson’s disease, has been introduced in the UK market by Renata PLC, a publicly traded pharmaceutical company.

This information was revealed by DSE sources.

According to sources, the first shipment of the drug has already reached the UK. Cabergoline, used to treat hyperprolactinemia and Parkinson’s disease, will be marketed locally in the country under the name Cabolin and will be manufactured in Bangladesh at Renata’s MHRA-approved manufacturing facility in the UK.

Earlier, Renata PLC launched a generic version of Cabergoline 0.5 mg in the Australian market in October last year. The drug, marketed under the brand name Dostomin, is distributed and commercialized in Australia through Renata’s partner Nova Pharmaceuticals Australasia Pty Ltd.

Cabergoline 0.5 mg is manufactured at Renata’s Mirpur facility, which is approved by both the Australian Therapeutic Goods Administration and the UK Medicines and Healthcare Products Regulatory Agency. In addition to the recent approval in Australia, Renata PLC has received approval for cabergoline in the UK and the European Union.